RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 250 participants.

Also called NCT07696975

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07696975
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07696975. Randomized; quadruple masking; primary purpose treatment. Start 2027-07-01 (anticipated); primary completion 2030-07-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
RELIEVE-HFrEF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure With Reduced EF
Acronym
RELIEVE-HFrEF
Condition
Heart Failure and Reduced Ejection Fraction
Condition
Heart Failure Chronic
Condition
Heart Failure New York Heart Association Class III
Condition
Heart Failure Congestive
Intervention (Device)
Implantation of the V-Wave Interatrial shunt
Intervention (Device)
Sham (no implant)
Lead sponsor
V-Wave Ltd (class: industry)
Collaborator
Johnson & Johnson (class: industry)

Record details

Record id
cardio:ct-nct07696975
Content hash
6cdd43e3f61bc5bf90a20c5e0eca724eade105f41fbd43f9a9f18dad160d8037